BioReference Laboratories, Inc. to Launch Groundbreaking Solid Tumor Genotyping Test through its GenPath Pharmaceuticals, Inc. Oncology Laboratory

ELMWOOD PARK, N.J.--(BUSINESS WIRE)--BioReference Laboratories, Inc. (NASDAQ: BRLI) and its GenPath Oncology business unit and through its exclusive commercialization agreement with the Massachusetts General Hospital (MGH) is introducing its groundbreaking solid tumor genotype test. The test – which will be marketed as OnkoMatchTM – will help oncologists match patients with cancer therapies tailored to a particular genetic mutation driving the disease and potentially identify additional patients who might qualify for clinical trials. Beginning on January 23, 2012, OnkoMatchTM will be available to community oncology practices and hospitals nationally through GenPath, making cutting edge technology accessible to patients around the country.